Nautilus Biotechnology, Inc. (NAUT)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-07-28) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-28) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-10-28) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-31) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-04-29) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-27) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-10-29) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-30) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-04-30) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-28) | ||
| 10-Q | Q3-2023 | 8-K (2023-10-31) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Comprehensive Loss | ||
| Consolidated Statements of Stockholders Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders Equity (deficit) | — |
|
| Notes | ||
| Basic and Diluted Net Loss Per Share | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Composition of Certain Condensed Consolidated Financial Statement Line Items | — |
|
| Composition of Certain Consolidated Financial Statement Line Items | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Description of Business and Basis of Presentation | ||
| Equity Incentive Plans and Stock-based Compensation | ||
| Fair Value Measurements | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Pay Vs Performance Disclosure | ||
| Segment Information | ||
| Significant Accounting Policies | ||